Intestinal Microbiome Biomarkers for PD-1 Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting treatment response to PD-1/PD-L1 blockade in cancer immunotherapy are inaccurate due to dynamic and spatial changes in PD-L1 expression, leading to ineffective treatment for some patients.
Innovation Solution
Develop a method to predict treatment response by evaluating the enrichment of specific bacterial clades, particularly the TANB77 taxa, in the intestinal microbiome of patients before treatment, using GTDB and NCBI phylogenetic classifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PD-L1 expression by immunohistochemistry is used as a predictive biomarker, then treatment response prediction is attempted, but the accuracy is not high enough to determine drug efficacy
Solution Approach 1:
The patent introduces intestinal microbiome composition as an intermediary biomarker that mediates between the treatment plan and the patient's actual response. The microbiome serves as a biological mediator that reflects the patient's immune system state and predicts response to immunotherapy, overcoming the limitations of direct tumor PD-L1 expression measurement.
Solution Approach 2:
The patent shifts the prediction parameter from tumor-derived PD-L1 expression levels to microbiome-derived bacterial composition profiles. This parameter change involves measuring the abundance and diversity of specific bacterial taxa in the patient's intestinal microbiome, which has been shown to correlate with immunotherapy response.
2Measurement precision
If PD-L1 expression is used for prediction, then some prediction is achieved, but the expression is dynamic and may change temporally and spatially leading to adaptive immune resistance
Solution Approach 1:
The patent performs microbiome analysis before initiating immunotherapy treatment. By assessing the intestinal microbiome composition in advance, the system predicts future treatment response without being affected by temporal changes in tumor characteristics during treatment. This preliminary assessment captures the patient's baseline immune system state.
Solution Approach 2:
The intestinal microbiome serves as a stable intermediary that reflects the patient's constitutive immune system characteristics. Unlike dynamic tumor PD-L1 expression, the microbiome composition remains relatively stable and provides a consistent predictive signal that is not subject to adaptive immune resistance mechanisms.
3Adaptability or versatility
If PD-L1 expression-negative patients are treated with PD-1/PD-L1 blockade, then treatment is administered, but some patients do not respond despite negative expression
Solution Approach 1:
The patent changes the selection parameter from binary PD-L1 expression status (positive/negative) to a continuous microbiome composition profile. This allows for more nuanced patient stratification and identifies responsive patients among those who would traditionally be classified as PD-L1 negative, thereby improving treatment reliability without reducing applicability.
Solution Approach 2:
The patent uses microbiome composition as a feedback mechanism to guide treatment decisions. By analyzing the patient's microbiome profile, the system provides feedback on predicted treatment response, allowing clinicians to adjust treatment plans for patients who might otherwise be excluded based on PD-L1 status alone.
Data Source
AI summary
Provided are a method for predicting a treatment response to cancer immunotherapy, the method comprising a step of evaluating, from feces isolated from a patient, the enrichment of a strain of the order TANB77 according to GTDB phylogenetic classification or taxa belonging to the order TANB77, and a step of predicting a treatment response of the patient to cancer immunotherapy on the basis of the enrichment of the order TANB77 or the taxa; a probiotics composition for improving a treatment response; a fecal microbiota transplantation composition; and a method for screening for candidate prebiotics by using same.